Cargando…
Redox/NIR dual-responsive MoS(2) for synergetic chemo-photothermal therapy of cancer
BACKGROUND: The construction of a multifunctional drug delivery system with a variety of advantageous features, including targeted delivery, controlled release and combined therapy, is highly attractive but remains a challenge. RESULTS: In this study, we developed a MoS(2)-based hyaluronic acid (HA)...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607525/ https://www.ncbi.nlm.nih.gov/pubmed/31269964 http://dx.doi.org/10.1186/s12951-019-0510-2 |
_version_ | 1783432111492956160 |
---|---|
author | Liu, Jian Li, Feiyang Zheng, Junxia Li, Bifei Zhang, Doudou Jia, Lee |
author_facet | Liu, Jian Li, Feiyang Zheng, Junxia Li, Bifei Zhang, Doudou Jia, Lee |
author_sort | Liu, Jian |
collection | PubMed |
description | BACKGROUND: The construction of a multifunctional drug delivery system with a variety of advantageous features, including targeted delivery, controlled release and combined therapy, is highly attractive but remains a challenge. RESULTS: In this study, we developed a MoS(2)-based hyaluronic acid (HA)-functionalized nanoplatform capable of achieving targeted delivery of camptothecin (CPT) and dual-stimuli-responsive drug release. HA was connected to MoS(2) via a disulfide linkage, forming a sheddable HA shell on the surface of MoS(2). This unique design not only effectively prevented the encapsulated CPT from randomly leaking during blood circulation but also significantly accelerated the drug release in response to tumor-associated glutathione (GSH). Moreover, the MoS(2)-based generated heat upon near-infrared (NIR) irradiation could further increase the drug release rate as well as induce photothermal ablation of cancer cells. The results of in vitro and in vivo experiments revealed that MoS(2)–SS–HA–CPT effectively suppressed cell proliferation and inhibited tumor growth in lung cancer cell-bearing mice under NIR irradiation via synergetic chemo-photothermal therapy. CONCLUSIONS: The as-prepared MoS(2)–SS–HA–CPT with high targeting ability, dual-stimuli-responsive drug release, and synergistic chemo-photothermal therapy may provide a new strategy for cancer therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12951-019-0510-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6607525 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-66075252019-07-12 Redox/NIR dual-responsive MoS(2) for synergetic chemo-photothermal therapy of cancer Liu, Jian Li, Feiyang Zheng, Junxia Li, Bifei Zhang, Doudou Jia, Lee J Nanobiotechnology Research BACKGROUND: The construction of a multifunctional drug delivery system with a variety of advantageous features, including targeted delivery, controlled release and combined therapy, is highly attractive but remains a challenge. RESULTS: In this study, we developed a MoS(2)-based hyaluronic acid (HA)-functionalized nanoplatform capable of achieving targeted delivery of camptothecin (CPT) and dual-stimuli-responsive drug release. HA was connected to MoS(2) via a disulfide linkage, forming a sheddable HA shell on the surface of MoS(2). This unique design not only effectively prevented the encapsulated CPT from randomly leaking during blood circulation but also significantly accelerated the drug release in response to tumor-associated glutathione (GSH). Moreover, the MoS(2)-based generated heat upon near-infrared (NIR) irradiation could further increase the drug release rate as well as induce photothermal ablation of cancer cells. The results of in vitro and in vivo experiments revealed that MoS(2)–SS–HA–CPT effectively suppressed cell proliferation and inhibited tumor growth in lung cancer cell-bearing mice under NIR irradiation via synergetic chemo-photothermal therapy. CONCLUSIONS: The as-prepared MoS(2)–SS–HA–CPT with high targeting ability, dual-stimuli-responsive drug release, and synergistic chemo-photothermal therapy may provide a new strategy for cancer therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12951-019-0510-2) contains supplementary material, which is available to authorized users. BioMed Central 2019-07-03 /pmc/articles/PMC6607525/ /pubmed/31269964 http://dx.doi.org/10.1186/s12951-019-0510-2 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Liu, Jian Li, Feiyang Zheng, Junxia Li, Bifei Zhang, Doudou Jia, Lee Redox/NIR dual-responsive MoS(2) for synergetic chemo-photothermal therapy of cancer |
title | Redox/NIR dual-responsive MoS(2) for synergetic chemo-photothermal therapy of cancer |
title_full | Redox/NIR dual-responsive MoS(2) for synergetic chemo-photothermal therapy of cancer |
title_fullStr | Redox/NIR dual-responsive MoS(2) for synergetic chemo-photothermal therapy of cancer |
title_full_unstemmed | Redox/NIR dual-responsive MoS(2) for synergetic chemo-photothermal therapy of cancer |
title_short | Redox/NIR dual-responsive MoS(2) for synergetic chemo-photothermal therapy of cancer |
title_sort | redox/nir dual-responsive mos(2) for synergetic chemo-photothermal therapy of cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607525/ https://www.ncbi.nlm.nih.gov/pubmed/31269964 http://dx.doi.org/10.1186/s12951-019-0510-2 |
work_keys_str_mv | AT liujian redoxnirdualresponsivemos2forsynergeticchemophotothermaltherapyofcancer AT lifeiyang redoxnirdualresponsivemos2forsynergeticchemophotothermaltherapyofcancer AT zhengjunxia redoxnirdualresponsivemos2forsynergeticchemophotothermaltherapyofcancer AT libifei redoxnirdualresponsivemos2forsynergeticchemophotothermaltherapyofcancer AT zhangdoudou redoxnirdualresponsivemos2forsynergeticchemophotothermaltherapyofcancer AT jialee redoxnirdualresponsivemos2forsynergeticchemophotothermaltherapyofcancer |